psoralen
potent
smallmolecul
blocker
voltageg
potassium
channel
current
preclin
develop
psoriasi
present
studi
undertaken
identifi
major
phasei
metabolit
rat
follow
oral
administr
mgkg
bile
plasma
urin
fece
collect
separ
reversedphas
hplc
sampl
prepar
solidphas
extract
five
phasei
metabolit
ie
oxybutyricacid
psoralen
psoralen
psoralen
psoralen
psoralen
isol
identifi
mass
spectrometri
nmr
spectroscopi
hydroxyl
product
odealkyl
product
incub
rat
liver
microsom
render
five
major
metabolit
nadphdepend
manner
suggest
cytochrom
cyp
enzym
involv
metabol
inhibitor
rat
alphanaphthoflavon
ketoconazol
block
metabol
rat
microsom
five
metabolit
found
inhibit
current
nanomolar
ic
inact
result
identifi
major
phasei
metabolit
suggest
hydroxyl
odealkyl
major
pathway
metabol
princip
via
conduct
repeatdos
toxic
studi
mgkg
male
femal
rat
observ
chang
hematolog
blood
chemistri
bodi
weight
histolog
major
organ
speed
metabol
suggest
induct
metabol
enzym
presum
cyp
keyword
psoralen
blocker
metabol
human
tlymphocyt
primarili
express
two
potassium
channel
voltageg
potassium
channel
calcium
activ
potassium
channel
logsdon
et
al
cahalan
chandi
cell
activ
channel
play
import
role
regul
membran
potenti
promot
countercurr
efflux
potassium
allow
influx
extracellular
calcium
calcium
releaseactiv
calcium
channel
chandi
et
al
cahalan
chandi
blockad
consequ
lead
membran
depolar
thu
reduc
ca
influx
result
prevent
tcell
activ
chandi
et
al
base
increas
express
activ
effector
memori
cell
channel
particular
identifi
therapeut
target
select
suppress
cell
autoimmun
diseas
diabet
multipl
sclerosi
psoriasi
beeton
et
al
wulff
et
al
peptid
kaliotoxin
scorpion
venom
shk
sea
anemon
stichodactyla
helianthu
select
deriv
shk
shown
prevent
revers
symptom
experiment
autoimmun
encephalomyel
eae
beeton
et
al
beeton
et
al
beeton
et
al
pristan
induc
arthriti
beeton
et
al
howev
point
clinic
applic
small
molecular
blocker
oral
administr
would
highli
desir
current
potent
select
avail
small
molecul
blocker
psoralen
block
channel
ic
approxim
nm
exhibit
select
select
channel
respect
demonstr
suppress
delayedtyp
hypersensit
prevent
diabet
develop
autoimmun
diabet
prone
rat
beeton
et
al
inhibit
oxazoloneinduc
allerg
contact
dermat
acd
simpl
rat
model
psoriasi
azam
et
al
base
fact
suppress
acd
intraperiton
oral
administr
also
follow
topic
applic
compound
current
preclin
develop
treatment
psoriasi
moreov
display
sign
acut
toxic
vitro
vivo
prevent
develop
flu
vaccin
respons
primat
pereira
et
al
although
pharmacokinet
report
rat
rhesu
macaqu
beeton
et
al
azam
et
al
pereira
et
al
metabol
still
unclear
none
metabolit
identifi
particular
clear
whether
potenti
toxicophor
psoralen
group
exhibit
toxic
vivo
addit
possibl
exhibit
phototox
alreadi
demonstr
case
metabolit
result
initi
oxid
metabol
furan
ring
psoralen
moieti
also
potenti
toxic
shown
suicid
inhibitor
cyp
cytochrom
psoralen
trager
baumgart
et
al
furan
ring
import
site
metabol
alter
psoralen
deriv
gener
extrem
reactiv
carbonyl
via
epoxid
metabolit
capabl
bind
coval
macromolecul
includ
metabol
enzym
suggest
respons
carcinogen
mutagen
hepatotox
observ
psoralen
da
silva
et
al
gain
deeper
insight
metabol
fate
examin
biotransform
compound
oral
administr
rat
preliminari
experi
identifi
metabolit
bile
matrix
plasma
urin
fece
aim
studi
undertaken
isol
identifi
major
phasei
metabolit
rat
plasma
urin
fece
particularli
bile
test
identifi
metabolit
activ
postul
metabol
pathway
base
ex
vivo
vitro
liver
micorsom
incub
result
synthes
depart
pharmacolog
univers
california
davi
davi
ca
usa
previous
describ
glucos
nadp
glucos
dehydrogenas
alphanaphthoflavon
diethyldithiocarbam
quinidin
sulfaphenazol
obtain
sigma
chemic
co
st
loui
mo
usa
ketoconazol
provid
nanj
baijingyu
pharmaceut
factori
nanj
china
chemic
analyt
grade
hplc
grade
hplc
carri
integr
system
shimadzu
kyoto
japan
uvvi
detector
metabolit
separ
reversedphas
column
c
mm
mm
id
unimicro
china
mobil
phase
consist
three
solvent
formic
acid
water
b
acetonitril
c
methanol
follow
linear
gradient
min
min
min
min
min
c
maintain
time
flow
rate
mlmin
column
temperatur
set
absorb
monitor
nm
mass
spectrometr
analys
perform
use
lcmsittof
shimadzu
kyoto
japan
esi
sourc
follow
condit
formic
acid
water
acetonitril
flow
rate
mlmin
esi
posit
scan
mode
nebul
ga
lmin
cdl
temperatur
interfac
temperatur
ion
accumul
time
ms
ms
scan
rang
mz
detector
voltag
kv
data
acquisit
process
carri
lcmssolut
softwar
version
hnmr
spectra
obtain
deuteromethanol
cd
od
avanc
iii
nmr
spectromet
bruker
biospin
corp
billerica
usa
mhz
spectromet
control
use
topspin
bruker
biospin
v
pl
sampl
dissolv
ml
cd
od
place
magnet
depth
male
spraguedawley
rat
weigh
g
purchas
shanghai
slac
laboratori
anim
co
ltd
shanghai
china
acclimat
least
week
standard
diet
ad
libitum
kept
control
h
lightdark
cycl
room
temperatur
rel
humid
mgkg
peanut
oil
oral
administ
rat
fast
hour
access
water
bile
duct
cannul
tube
rat
anesthet
ether
bile
sampl
continu
collect
hour
three
rat
place
metabol
cage
collect
sampl
urin
fece
continu
hour
ml
blood
also
collect
anesthet
rat
h
administr
mesenter
vein
abdomin
arteri
plasma
obtain
centrifug
sampl
store
hplc
analysi
metabol
studi
conduct
approv
experiment
anim
care
use
committe
school
pharmaci
shanghai
jiao
tong
univers
toxic
studi
see
approv
institut
anim
care
use
committe
univers
california
davi
bile
sampl
ml
mix
phosphor
acid
ml
acet
ether
ml
nhexan
minut
vortex
mixtur
centrifug
g
minut
room
temperatur
organ
phase
remov
evapor
dryness
n
residu
reconstitut
methanol
solut
inject
hplc
system
plasma
urin
fece
sampl
also
treat
except
fece
sampl
prior
extract
methanol
multiplestep
elut
procedur
develop
use
solidphas
extract
spe
column
would
allow
us
isol
metabolit
bile
accord
differ
lipophilicti
see
fig
scheme
spe
procedur
briefli
describ
rat
bile
sampl
thaw
water
bath
room
temperatur
centrifug
g
minut
ml
aliquot
result
supernat
load
onto
cartridg
mg
supelco
bellefont
pa
usa
previous
condit
ml
methanol
ml
deioniz
water
fraction
collect
elut
ml
methanol
respect
first
eluant
fraction
sampl
combin
acidifi
ph
hcl
appli
second
cartridg
subsequ
wash
ml
methanol
prior
elut
final
fraction
ml
methanol
discard
dri
n
redissolv
methanol
separ
hplc
eluant
correspond
metabolit
collect
combin
evapor
dryness
subject
lcmsittof
hnmr
analysi
rat
liver
microsom
prepar
describ
previous
hill
briefli
liver
remov
rapidli
perfus
pale
brown
icecold
homogen
buffer
trishcl
ph
mm
edta
mm
kcl
cut
piec
homogen
icecold
homogen
buffer
microsom
protein
separ
differenti
ultracentrifug
result
pellet
resuspend
icecold
microsom
buffer
trishcl
ph
mm
edta
glycerol
store
content
microsom
protein
determin
use
bradford
protein
assay
kit
purchas
tiangen
biotech
co
ltd
beij
china
metabolit
obtain
hplc
separ
incub
nadphregener
system
mm
uml
dehydrogenas
mm
nadp
mm
mgcl
contain
rat
liver
microsom
mg
proteinml
final
incub
volum
reaction
initi
addit
nadphregener
system
preincub
period
continu
minut
eppendorf
thermomix
compact
incub
termin
addit
phosphor
acid
ml
ethyl
acet
follow
vortex
centrifug
g
minut
ml
organ
layer
dri
stream
nitrogen
ga
residu
reconstitut
methanol
analyz
hplc
identifi
metabolit
effect
cyp
isoenzym
metabol
also
evalu
use
five
select
inhibitor
includ
alphanaphthoflavon
rat
quinidin
rat
diethyldithiocarbam
rat
sulfaphenazol
rat
ketoconazol
rat
daniel
et
al
martignoni
de
kanter
erickson
et
al
variou
concentr
inhibitor
preincub
rat
liver
microsom
minut
follow
addit
incub
mixtur
prewarm
minut
addit
nadph
regener
system
incub
minut
termin
describ
metabolit
incub
mixtur
determin
use
hplc
system
effect
metabolit
block
assay
cell
stabli
express
grissmer
et
al
experi
control
heka
amplifi
puls
softwar
heka
bellmor
ny
lambrecht
germani
patch
pipett
pull
soda
lime
glass
resist
submerg
bath
solut
experi
conduct
wholecel
configur
patchclamp
techniqu
hold
potenti
mv
current
record
normal
ringer
solut
mm
nacl
mm
kcl
mm
cacl
mm
mgcl
mm
hepe
ph
mosm
intern
pipett
solut
contain
mm
kf
mm
mgcl
mm
hepe
mm
egta
ph
mosm
current
exceed
na
seri
resist
compens
use
depolar
puls
mv
appli
everi
ms
ic
valu
determin
fit
reduct
area
current
curv
hill
equat
data
analysi
fit
plot
perform
igorpro
wavemetr
lake
oswego
usa
origin
softwar
originlab
northampton
usa
femal
male
week
old
lewi
rat
purchas
charl
river
gavag
daili
month
either
mgkg
n
male
femal
rat
vehicl
peanut
oil
ml
per
kg
bodi
weight
n
male
femal
rat
end
trial
rat
sacrif
complet
blood
chemistri
hematolog
necropsi
perform
compar
patholog
laboratori
univers
california
davi
briefli
whole
anim
weight
mg
determin
use
ohau
analyt
scale
rat
euthan
co
blood
collect
via
cardiac
punctur
ml
sampl
place
edta
coat
samplett
tube
determin
hematolog
profil
rest
blood
place
serum
separ
samplett
tube
separ
centrifug
rpm
minut
hematolog
profil
perform
drew
mascot
autom
cell
counter
includ
rbc
count
mean
corpuscular
hb
wbc
count
mean
corpuscular
volum
platelet
count
reticulocyt
count
hematocrit
wbc
differenti
hb
concentr
blood
cell
morpholog
evalu
manual
microscopi
serum
chemistri
perform
coba
mira
plu
chemistri
analyz
includ
alanin
aminotransferas
aspart
aminotransferas
alkalin
phosphatas
calcium
phosphoru
blood
urea
nitrogen
creatinin
glucos
total
protein
albumin
total
bilirubin
cholestrol
triglycerid
necropsi
spleen
thymu
liver
kidney
dissect
weigh
mg
use
ohau
analyt
scale
pelag
cecalintestin
content
sampl
examin
microscop
parasit
cultur
taken
nasopharynx
cecal
wall
presenc
aerob
bacteria
includ
potenti
opportunist
pathogen
liver
kidney
spleen
gi
tract
pancrea
lung
heart
brain
bone
marrow
proxim
distal
lymph
node
thymu
gonad
collect
fix
buffer
formalin
tissu
section
process
paraffin
block
use
routin
method
hematoxylin
eosin
stain
section
block
examin
histolog
chang
train
pathologist
serolog
perform
elisa
test
follow
infecti
agent
data
express
mean
standard
deviat
statist
signific
determin
p
use
unpair
twotail
student
ttest
bile
sampl
continu
collect
hour
follow
oral
administr
mgkg
extract
organ
solvent
describ
method
analyz
hplc
five
phasei
metabolit
found
bile
fig
elut
min
polar
metabolit
elut
min
min
min
min
min
respect
five
metabolit
also
present
fece
fig
contrast
bile
major
metabolit
abandon
metabolit
fece
hand
could
detect
abdomin
arteri
plasma
mesenter
venou
plasma
alon
detect
urin
sampl
fig
next
want
determin
structur
five
metabolit
spe
procedur
see
fig
found
ph
sampl
solut
significantli
affect
retent
spe
cartridg
basic
condit
origin
bile
sampl
carboxyl
acid
function
molecul
would
exist
almost
exclus
ioniz
form
lipophil
psoralen
group
still
ensur
retain
spe
cartridg
easili
elut
methanol
elut
acidifi
ph
elut
methanol
due
stronger
retent
thu
help
spe
could
isol
bile
puriti
yield
mg
approxim
ml
bile
four
metabolit
bile
also
prepar
use
spe
hplc
describ
method
mg
mg
mg
mg
amorph
white
powder
amorph
grayishwhit
powder
determin
structur
isol
metabolit
mass
spectrometri
hnmr
hnmr
exhibit
characterist
proton
signal
psoralen
moieti
two
coupl
proton
coumarin
ring
doubl
bond
j
hz
j
hz
aromat
singlet
two
coupl
proton
furan
ring
j
hz
j
hz
tabl
metabolit
oxybutyricacid
psoralenth
mass
spectrum
exhibit
pseudomolecular
ion
mh
mz
compat
molecular
formula
c
h
calcul
molecular
weight
fig
ms
spectrum
major
product
ion
mz
present
form
cleavag
ether
bond
psoralen
ring
butyr
acid
side
chain
hnmr
exhibit
characterist
proton
signal
psoralen
system
set
proton
butano
acid
chain
j
hz
ch
ch
cooh
j
hz
ch
ch
cooh
ch
ch
cooh
tabl
comparison
hnmr
data
show
miss
sidechain
phenyl
ring
basi
evid
structur
elucid
oxi
butano
acid
compound
previous
report
synthes
intermedi
product
ropp
et
al
j
hz
j
hz
j
hz
j
hz
j
hz
ch
ch
ch
oh
j
hz
ch
ch
ch
oh
ch
ch
ch
oh
tabl
comparison
hnmr
data
suggest
ident
except
downfield
shift
repres
h
hydroxybutoxi
group
base
analysi
hnmr
spectral
data
structur
deduc
compound
report
previous
metabolit
psoralenth
ms
spectrum
show
pseudomolecular
ion
mh
mz
compat
molecular
formula
c
h
calcul
molecular
weight
fig
mass
unit
suggest
hydroxyl
product
ms
spectrum
fragment
ion
appear
mz
indic
hydroxi
group
locat
side
chain
hnmr
ppm
j
hz
j
hz
j
hz
j
hz
ch
ch
ch
oc
h
oh
j
hz
j
hz
ch
ch
ch
oc
h
oh
j
hz
ch
ch
ch
oc
h
oh
ch
ch
ch
oc
h
oh
tabl
symmetr
quartet
hnmr
spectrum
suggest
hydrogen
atom
paraposit
phenyl
ring
replac
hydroxyl
group
thu
structur
compound
elucid
butoxi
compound
report
previous
ms
spectrum
show
pseudomolecular
ion
mh
mz
compat
molecular
formula
c
h
calcul
molecular
weight
fig
ms
ms
spectra
suggest
also
hydroxyl
product
hnmr
ppm
j
hz
j
hz
j
hz
h
h
j
hz
j
hz
ch
ch
ch
oc
h
oh
j
hz
ch
ch
ch
oc
h
oh
ch
ch
ch
oc
h
oh
tabl
hnmr
data
similar
except
multiplet
h
show
hydroxyl
group
link
meta
posit
phenyl
ring
base
spectral
evid
structur
compound
elucid
butoxi
report
previous
mz
compat
molecular
formula
c
h
calcul
molecular
weight
fig
molecular
formula
mass
unit
higher
suggest
hydroxyl
product
ms
spectrum
two
fragment
ion
appear
mz
indic
hydroxyl
occur
psoralen
ring
hnmr
show
ppm
j
hz
j
hz
h
j
hz
h
j
hz
j
hz
ch
ch
ch
oc
h
j
hz
ch
ch
ch
oc
h
ch
ch
ch
oc
h
tabl
hnmr
data
similar
except
absenc
psoralen
ring
spectral
evid
structur
compound
elucid
compound
report
previous
sinc
incub
liver
microsom
could
potenti
offer
addit
valuabl
inform
interpret
relationship
among
metabolit
reveal
metabol
pathway
incub
rat
liver
microsom
presenc
nadph
rapidli
metabol
abovedescrib
five
metabolit
detect
hplc
contrast
control
incub
without
nadph
incub
condit
rat
microsom
metabol
metabol
one
metabolit
detect
follow
incub
rat
liver
microsom
two
metabolit
appear
incub
probabl
metabol
unknown
product
detect
bile
sampl
due
low
abund
result
shown
fig
thu
identifi
five
major
phasei
metabolit
novel
experiment
immunosuppress
gener
nadphdepend
manner
suggest
cyp
enzym
play
major
role
metabol
three
metabolit
psoralen
psoralen
psoralen
hydroxyl
molecular
mass
howev
dealkyl
complet
sidechain
detect
sampl
peak
found
extract
ion
chromatogram
lcmsittof
mh
mz
z
mz
phenol
order
identifi
cyp
isoenzym
princip
respons
metabol
rat
liver
microsom
prepar
use
five
select
inhibitor
rat
specif
probe
daniel
et
al
martignoni
erickson
et
al
sinc
report
import
cyp
isoenzym
rat
elsherbini
et
al
follow
incub
liver
microsom
quadrupl
determin
concentr
five
metabolit
plot
percentag
correspond
control
area
peak
inhibitor
alphanaphthoflavon
concentrationdepend
decreas
product
maximum
inhibit
respect
fig
inhibitor
ketoconazol
also
concentrationdepend
decreas
product
respect
fig
hand
inhibitor
quinidin
inhibitor
diethyldithiocarbam
inhibitor
sulphaphenazol
fail
significantli
affect
metabol
fig
result
suggest
princip
involv
hydroxyl
odealkyl
order
determin
identifi
metabolit
still
activ
next
test
effect
current
wholecel
patchclamp
fig
odealkyl
metabolit
exhibit
effect
fig
show
weak
block
activ
block
data
shown
concentr
hydroxyl
metabolit
potent
block
revers
fashion
fig
ic
nm
nm
nm
fig
similar
parent
compound
activ
metabolit
exhibit
hill
coeffici
suggest
molecul
interact
one
channel
zimin
et
al
sinc
treat
autoimmun
diseas
often
requir
longterm
lifelong
treatment
also
evalu
longterm
toxic
profil
inhibit
therapeut
dose
previous
shown
prevent
diabet
develop
beeton
et
al
suppress
allerg
contact
dermat
rat
azam
et
al
follow
administr
month
mgkg
daili
gavag
male
femal
lewi
rat
signific
chang
hematolog
blood
chemistri
observ
tabl
except
small
increas
cholesterol
treat
femal
mgdl
mgdl
small
decreas
blood
glucos
treat
male
mgdl
mgdl
probabl
rather
due
slightli
differ
time
sacrific
last
food
consumpt
drug
relat
respect
potenti
liver
toxic
noteworthi
longterm
treatment
result
elev
aspart
aminotransferas
alanin
aminitransferas
alkalin
phosphatas
treatment
also
result
chang
bodi
organ
weight
histopatholog
major
organ
liver
kidney
pancrea
lung
heart
brain
bone
marrow
gonad
sinc
previous
determin
pharmacokinet
rat
rhesu
macaqu
observ
follow
oral
applic
mgkg
plasma
valu
rise
peak
hour
applic
fall
nm
hour
beeton
et
al
also
measur
plasma
trough
concentr
hour
throughout
toxic
studi
plasma
trough
concentr
determin
hplcm
nm
month
nm
month
nm
demonstr
seem
induc
metabol
enzym
presum
cytochrom
enzym
accumul
time
keep
previous
publish
two
compart
model
pharmacokinet
beeton
et
al
azam
et
al
previou
studi
demonstr
rel
low
bioavail
rat
oral
administr
although
show
good
absorpt
gastrointestin
tract
rhesu
macaqu
pereira
et
al
predict
softwar
oral
avail
human
observ
low
bioavail
rat
presum
mainli
due
larg
hepat
firstpass
effect
oral
administ
rat
five
phasei
metabolit
structur
identifi
bile
carboxyl
acid
metabolit
hydroxyl
metabolit
metabolit
report
previou
studi
intermedi
synthesi
ropp
et
al
four
metabolit
identifi
new
chemic
entiti
ie
psoralen
psoralen
psoralen
psoralen
aka
bergapten
aka
xanthotoxin
two
compound
use
phototherapi
psoriasi
natur
occur
rutacea
plant
citru
metabol
rat
hydrolysi
lacton
ring
oxid
furan
ring
may
et
al
john
et
al
studi
suggest
epoxid
furan
ring
psoralen
gener
reactiv
intermedi
respons
toxic
psoralen
compound
inactiv
cyp
trager
caffieri
contrast
maintain
intact
psoralen
structur
biotransform
base
present
studi
major
metabolit
polar
carboxyl
acid
facilit
excret
without
metabol
suggest
exhibit
much
less
toxic
psoralen
keep
suggest
longterm
administr
induc
chang
plasma
liver
enzym
liver
histopatholog
sinc
psoralen
core
stay
intact
metabol
thought
like
sever
metabolit
might
still
activ
blocker
keep
sar
phenoxyalkoxypsoralentyp
blocker
recent
publish
bindingsit
model
zimin
et
al
odealkyl
found
inact
observ
surpris
sinc
phenoxybutoxi
sidechain
insert
lipophil
interphas
transmembran
segment
lack
phenyl
ring
well
polar
carboxyl
acid
function
would
disrupt
hydrophob
interact
hydroxyl
metabolit
contrast
exhibit
nanomolar
potenc
find
parasubstitut
ic
nm
potent
metasubstitut
ic
nm
confirmatori
previous
studi
sar
deriv
substitut
sidechain
phenyl
ring
parent
drug
five
metabolit
found
bile
fece
sampl
metabolit
detect
plasma
deriv
mesenter
vein
abdomin
arteri
metabolit
alon
present
urin
dealkyl
complet
sidechain
detect
sampl
result
suggest
follow
absorpt
intestin
metabol
extens
liver
follow
two
possibl
rout
five
metabolit
excret
across
canalicular
membran
bile
transport
across
sinusoid
membran
hepatocyt
circul
hypothes
metabolit
bile
excret
duodenum
reabsorb
later
due
fact
present
mesenter
venou
blood
high
concentr
similar
bile
littl
fece
detect
follow
incub
intestin
microsom
data
shown
effect
absorpt
system
circul
predominantli
elimin
kidney
metabolit
contrast
seem
reabsorb
intestin
directli
excret
fece
detect
plasma
mesenter
vein
appear
larg
amount
fece
base
observ
propos
major
circul
metabolit
biolog
activ
well
toxic
focu
studi
although
demonstr
ineffect
therefor
like
devoid
immunosuppress
activ
addit
five
metabolit
hydroxyl
group
may
go
phaseii
conjug
reaction
glucuron
acid
sulfur
acid
significantli
higher
concentr
fece
bile
suggest
like
releas
hydrolysi
phaseii
metabolit
fact
metabolit
could
detect
plasma
suggest
contribut
immunosuppress
activ
metabol
stabil
five
isol
metabolit
determin
vitro
liver
microsom
incub
rat
liver
microsom
presenc
nadph
five
metabolit
observ
contrast
neg
result
control
incub
without
nadph
indic
format
metabolit
enzymat
nadphdepend
vitro
metabolit
five
metabolit
found
bile
follow
vivo
metabol
furthermor
convert
microsom
incub
transform
suggest
odealkyl
major
metabol
reaction
liver
neither
detect
incub
confirm
observ
nmr
experi
name
hydroxyl
group
locat
sidechain
phenyl
ring
instead
psoralen
ring
system
could
form
odealkyl
format
correspond
aldehyd
immedi
reduc
alcohol
oxid
acid
thu
hydroxyl
odealkyl
would
major
metabol
pathway
odealkyl
would
probabl
major
pathway
inactiv
shown
fig
cyp
isoenzym
inhibit
studi
select
rat
inhibitor
alphanaphthoflavon
rat
inhibitor
ketoconazol
consid
enzymeselect
baririan
et
al
significantli
inhibit
format
suggest
mediat
odealkyl
involv
odealkyl
also
demonstr
applic
alphanaphthoflavon
ketoconazol
monostori
et
al
baririan
et
al
addit
format
monohydroxyl
analog
also
inhibit
two
inhibitor
inhibitor
quinidin
inhibitor
diethyldithiocarbam
inhibitor
sulphaphenazol
affect
either
odealkyl
hydroxyl
result
suggest
appear
major
isoenzym
involv
metabol
via
aromat
odealkyl
hydroxyl
also
present
fig
studi
warrant
incub
rat
human
pure
cyp
isoenzym
vivo
inhibit
metabol
conclus
result
show
hydroxyl
odealkyl
princip
via
major
metabol
pathway
experiment
immunosuppress
rat
liver
microsom
vivo
five
metabolit
includ
oxybutyricacid
psoralen
psoralen
psoralen
psoralen
reduc
activ
major
metabolit
entir
lost
activ
result
demonstr
longterm
administr
produc
signific
chang
hematolog
blood
chemistri
histolog
major
organ
speed
metabol
indic
enzym
presum
cytochrom
enzym
induct
solidphas
extract
spe
separ
scheme
rat
bile
bile
sampl
load
onto
cartridg
three
fraction
collect
elut
methanol
respect
eluant
combin
acidifi
hcl
appli
second
cartridg
wash
methanol
elut
methanol
repres
hplc
chromatogram
psoralen
metabolit
rat
follow
oral
administr
mgkg
five
major
metabolit
rat
bile
continu
collect
hr
dose
elut
min
min
min
min
min
min
respect
b
fece
collect
h
postdos
c
plasma
mesenter
vein
abdomin
arteri
h
oral
administr
urin
continu
hr
dose
effect
select
rat
cytochrom
isoenzym
inhibitor
metabol
psoralen
rat
liver
microsom
n
point
valu
given
mean
standard
deviat
alphanaphthoflavon
isoform
b
quinidin
c
ketoconazol
diethyldithiocarbam
isoform
e
sulphaphenazol
isoform
propos
metabol
pathway
psoralen
rat
